A
Ambrx
A biopharmaceutical company with a mission to deliver breakthrough protein therapeutics
At a glance
- Status
- Listed
- Listing
- IPO 2021
News
Open roles
Ambrx in the San Diego ecosystem
The Ambrx office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
- MVM Ventures
Series B and later21 investors entered at this stage
- TGTavistock Group
- UCUniversity of California
- BEBerkeley
BlackRock- SGSinopharm Group
- ACAdage Capital
- ACApricot Capital
- RFRoche Venture Fund
Versant Ventures- CLChina Everbright Limited
- CCCMEA Capital
Cormorant Asset Management- 5V5AM Ventures
- NSNortheast Securities
- MCMaverick Capital
Fidelity Investments- INInvus
- ACApposite Capital
- AVAravis Ventures
- SMSuvretta Capital Management
- MIMaverick Ventures Israel
Source: Dealroom Talent Intelligence.
Alumni founders
Former Ambrx employees who went on to found companies, sorted by Dealroom signal score.
ARArdelyxEst. 2007
APAblaze PharmaceuticalsEst. 2021
Alan XuChina
ABAvidity BiosciencesEst. 2013
Troy WilsonUnited States
ETEffector TherapeuticsEst. 2012
Kevin EastwoodUnited StatesPatents
43 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
See Ambrx on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


